ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the Company’s GenPath division. GenPath also offers many other tests as a part of their personalized medicine offering. Some of these are CYP2D6 for tamoxifen resistance, CYP2C9/VKORC1 for warfarin metabolism, and UGT1A1 for irinotecan toxicity. With the addition of K-ras, GenPath has affirmed its stance on the need to promote personalized medicine to tailor the right therapy for the right patient.
